The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review

Oscar K. Serrano, Charito Love, Inessa A. Goldman, Kevin Huang, Nicole Ng, Tony Abraham, Raphaella Da Silva, Patricia Friedmann, Steven K. Libutti, Timothy J. Kennedy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy-proven GA and 207 (34.0%) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG-PET up-staged 31 (18.7%) patients while it down-staged 17 (10.2%) patients. Of patients who were up-staged, 20 (64.5%) developed progressive disease. Conclusions Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640-646.

Original languageEnglish (US)
Pages (from-to)640-646
Number of pages7
JournalJournal of Surgical Oncology
Volume113
Issue number6
DOIs
StatePublished - May 1 2016

Fingerprint

Stomach
Adenocarcinoma
Lymph Nodes
Neoplasms
Neoplasm Metastasis
Physicians
Biopsy

Keywords

  • 2-deoxy-2-[(18)F]fluoro- d -glucose
  • cancer
  • positron emission tomography
  • stomach

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

The value of FDG-PET in the staging of gastric adenocarcinoma : A single institution retrospective review. / Serrano, Oscar K.; Love, Charito; Goldman, Inessa A.; Huang, Kevin; Ng, Nicole; Abraham, Tony; Da Silva, Raphaella; Friedmann, Patricia; Libutti, Steven K.; Kennedy, Timothy J.

In: Journal of Surgical Oncology, Vol. 113, No. 6, 01.05.2016, p. 640-646.

Research output: Contribution to journalArticle

Serrano, Oscar K. ; Love, Charito ; Goldman, Inessa A. ; Huang, Kevin ; Ng, Nicole ; Abraham, Tony ; Da Silva, Raphaella ; Friedmann, Patricia ; Libutti, Steven K. ; Kennedy, Timothy J. / The value of FDG-PET in the staging of gastric adenocarcinoma : A single institution retrospective review. In: Journal of Surgical Oncology. 2016 ; Vol. 113, No. 6. pp. 640-646.
@article{262abcd0942e43c98a2c53c70affcc20,
title = "The value of FDG-PET in the staging of gastric adenocarcinoma: A single institution retrospective review",
abstract = "Background The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy-proven GA and 207 (34.0{\%}) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3{\%}) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3{\%}), 84 (50.6{\%}), 25 (15.1{\%}), and 32 (19.3{\%}) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3{\%}), 78 (47.0{\%}), 41 (24.7{\%}), and 27 (16.3{\%}) of patients, respectively. FDG-PET up-staged 31 (18.7{\%}) patients while it down-staged 17 (10.2{\%}) patients. Of patients who were up-staged, 20 (64.5{\%}) developed progressive disease. Conclusions Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9{\%}) patients. J. Surg. Oncol. 2016;113:640-646.",
keywords = "2-deoxy-2-[(18)F]fluoro- d -glucose, cancer, positron emission tomography, stomach",
author = "Serrano, {Oscar K.} and Charito Love and Goldman, {Inessa A.} and Kevin Huang and Nicole Ng and Tony Abraham and {Da Silva}, Raphaella and Patricia Friedmann and Libutti, {Steven K.} and Kennedy, {Timothy J.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/jso.24190",
language = "English (US)",
volume = "113",
pages = "640--646",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - The value of FDG-PET in the staging of gastric adenocarcinoma

T2 - A single institution retrospective review

AU - Serrano, Oscar K.

AU - Love, Charito

AU - Goldman, Inessa A.

AU - Huang, Kevin

AU - Ng, Nicole

AU - Abraham, Tony

AU - Da Silva, Raphaella

AU - Friedmann, Patricia

AU - Libutti, Steven K.

AU - Kennedy, Timothy J.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy-proven GA and 207 (34.0%) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG-PET up-staged 31 (18.7%) patients while it down-staged 17 (10.2%) patients. Of patients who were up-staged, 20 (64.5%) developed progressive disease. Conclusions Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640-646.

AB - Background The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy-proven GA and 207 (34.0%) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG-PET up-staged 31 (18.7%) patients while it down-staged 17 (10.2%) patients. Of patients who were up-staged, 20 (64.5%) developed progressive disease. Conclusions Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640-646.

KW - 2-deoxy-2-[(18)F]fluoro- d -glucose

KW - cancer

KW - positron emission tomography

KW - stomach

UR - http://www.scopus.com/inward/record.url?scp=84964443998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964443998&partnerID=8YFLogxK

U2 - 10.1002/jso.24190

DO - 10.1002/jso.24190

M3 - Article

C2 - 27115836

AN - SCOPUS:84964443998

VL - 113

SP - 640

EP - 646

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 6

ER -